Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$95.24 +0.45 (+0.47%)
As of 11:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
9
Buy
9

Based on 19 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 1 has given a sell rating, 9 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for ILMN.

Consensus Price Target

$127.39
33.76% Upside
According to the 19 analysts' twelve-month price targets for Illumina, the average price target is $127.39. The highest price target for ILMN is $200.00, while the lowest price target for ILMN is $85.00. The average price target represents a forecasted upside of 33.76% from the current price of $95.24.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
6/30/24 to 6/30/25
1 Month Ago
5/31/24 to 5/31/25
3 Months Ago
4/1/24 to 4/1/25
1 Year Ago
7/1/23 to 6/30/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
9 Hold rating(s)
10 Hold rating(s)
10 Hold rating(s)
11 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$127.39$128.15$140.90$158.14
Forecasted Upside33.76% Upside57.49% Upside79.74% Upside51.51% Upside
Consensus Rating
Hold
Hold
Hold
Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.81
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside33.97% Upside8,543.25% Upside12.42% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/24/2025Barclays
3 of 5 stars
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight$77.00 ➝ $85.00-6.30%
6/11/2025Canaccord Genuity Group
2 of 5 stars
Kyle Mikson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$87.00 ➝ $99.00+12.53%
5/20/2025Stephens
4 of 5 stars
Mason Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+26.58%
5/15/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$190.00 ➝ $185.00+129.39%
5/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tejas Savant
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$136.00 ➝ $100.00+24.99%
5/9/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Julia Qin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$120.00 ➝ $85.00+12.20%
5/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Subbu Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$122.00 ➝ $114.00+48.17%
4/8/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Conor McNamara
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$128.00 ➝ $112.00+51.28%
4/7/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$90.00 ➝ $85.00+18.37%
3/5/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Catherine Ramsey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$127.00 ➝ $90.00+6.02%
2/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
2/28/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$100.00+12.40%
2/7/2025TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brennan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$177.00 ➝ $140.00+14.01%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$133.00 ➝ $145.00-4.89%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$160.00 ➝ $200.00+38.91%
8/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$150.00+14.59%
8/16/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/16/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$120.00 ➝ $154.00+19.57%
8/15/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Outperform ➝ Sector Outperform$176.00 ➝ $164.00+27.33%
6/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$195.00 ➝ $175.00+59.35%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$140.00 ➝ $100.00-14.99%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+49.91%
8/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$225.00 ➝ $200.00+8.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:55 AM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 27, 2025. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • The current stock price is around $94.79, showing a recent increase, which may indicate positive market sentiment.
  • Illumina, Inc. has a strong market capitalization of approximately $15.01 billion, reflecting its significant presence in the life sciences sector.
  • Recent analyst ratings show a consensus of "Moderate Buy," suggesting that many experts believe the stock has potential for growth.
  • Institutional investors own a substantial 89.42% of the stock, indicating confidence from large financial entities in the company's future performance.
  • Illumina, Inc. has been actively involved in innovations in genomic sequencing, which positions it well for future growth in the expanding biotechnology market.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • The stock has a price-to-earnings ratio of -15.60, indicating that the company is currently not profitable, which can be a red flag for potential investors.
  • Recent price targets from analysts have been lowered, with some suggesting a target of $85.00, which may reflect concerns about the company's growth prospects.
  • Illumina, Inc. has faced increased competition in the genomic sequencing market, which could impact its market share and profitability.
  • There has been a notable decrease in holdings by some institutional investors, such as Wellington Management Group LLP, which may signal a lack of confidence in the stock's future performance.
  • The company has a relatively high debt-to-equity ratio of 0.63, which could indicate potential financial risk if not managed properly.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $127.39, with a high forecast of $200.00 and a low forecast of $85.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There is currently 1 sell rating, 9 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted upside of 33.76% based on their 12-month stock forecasts.

Illumina has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank Of Canada, and Stephens in the past 90 days.

Analysts like Illumina less than other "medical" companies. The consensus rating for Illumina is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners